The anti-SARS-CoV-2 monoclonal antibody bamlanivimab minimally affects the endogenous immune response to COVID-19 vaccination.
Benschop RJ, Tuttle JL, Zhang L, Poorbaugh J, Kallewaard NL, Vaillancourt P, Crisp M, Trinh TNV, Freitas JJ, Beasley S, Daniels M, Haustrup N, Higgs RE, Nirula A, Cohen MS, Marovich M.
Benschop RJ, et al. Among authors: daniels m.
Sci Transl Med. 2022 Jul 27;14(655):eabn3041. doi: 10.1126/scitranslmed.abn3041. Epub 2022 Jul 27.
Sci Transl Med. 2022.
PMID: 35679357
Free PMC article.
Clinical Trial.